News

Releases included below may include references to both on-label and off-label usage of the HeartLight® Endoscopic Ablation System.
14
May
2018
14 May 2018

CardioFocus® Announces Successful Live Case Featuring HeartLight® X3 System

MARLBOROUGH, Mass., May 9, 2018 /PRNewswire/ — CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced a successful live case featuring its breakthrough HeartLight X3 System during the annual Prague Workshop on Catheter Ablation.

07
May
2018
07 May 2018

CardioFocus® FDA Approval Of The Next-Generation HeartLight® Excalibur Balloon™ Designed For The Treatment Of Paroxysmal Atrial Fibrillation*

MARLBOROUGH, Mass., May 7, 2018 /PRNewswire/ — CardioFocus, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the HeartLight Excalibur Balloon, a next-generation technology designed for the treatment of paroxysmal atrial fibrillation (PAF)*.

26
Feb
2018
26 Feb 2018

CardioFocus® Announces Initiation of HeartLight® X3 Clinical Evaluation

MARLBOROUGH, Mass., February 26, 2018 /PRNewswire/ — CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced the initiation of a clinical evaluation of the new HeartLight X3 System for the treatment of AF.

09
Jan
2018
09 Jan 2018

CardioFocus® Announces Expanded Partnership With Japan Lifeline

MARLBOROUGH, Mass., January 9, 2018 /PRNewswire/ — CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced that it has entered into an expanded partnership with Japan Lifeline Co., Ltd. (JLL).

29
Nov
2017
29 Nov 2017

CardioFocus® Completes Successful Controlled U.S. Commercial Launch Of The HeartLight® System

MARLBOROUGH, Mass., November 29, 2017 /PRNewswire/ — CardioFocus, Inc. today announced the successful completion of its controlled U.S. commercial launch of the HeartLightEndoscopic Ablation System for the treatment of paroxysmal atrial fibrillation (AF).

27
Sep
2017
27 Sep 2017

CardioFocus® Announces European CE Mark Approval Of The Next-Generation HeartLight® Excalibur Balloon™ Designed For The Treatment Of Atrial Fibrillation

MARLBOROUGH, Mass., September 27, 2017 /PRNewswire/ — CardioFocus, Inc. today announced the European CE Mark approval of the HeartLight Excalibur Balloon, a next-generation technology designed for the treatment of atrial fibrillation (AF).

31
Jul
2017
31 Jul 2017

CardioFocus® Receives Approval For HeartLight® Endoscopic Ablation System From The Japanese Ministry Of Health, Labour And Welfare

MARLBOROUGH, Mass., July 31, 2017 /PRNewswire/ — CardioFocus, Inc. today announced that the Japanese Ministry of Health, Labour and Welfare has approved the HeartLight Endoscopic Ablation System for the treatment of paroxysmal atrial fibrillation (AF) in Japan.

29
Jun
2017
29 Jun 2017

CardioFocus®Announces Initiation Of Three Major Studies Featuring The HeartLight® System For The Treatment Of Atrial Fibrillation

MARLBOROUGH, Mass., Mar. 29, 2017 /PRNewswire/ — CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical studies currently underway. Collectively, up to 1,000 AF patients will be […]

06
Jun
2017
06 Jun 2017

Na Homolce Hospital Treats 500th Patient Using HeartLight Endoscopic Ablation System

MARLBOROUGH, Mass., June 6, 2017 /PRNewswire/ — CardioFocus, Inc. today announced the electrophysiology team at Na Homolce Hospital in Prague, Czech Republic is the first to successfully treat 500 patients using the HeartLight® Endoscopic Ablation System.

29
Mar
2017
29 Mar 2017

CardioFocus® Completes $20 Million Equity Financing

MARLBOROUGH, Mass., Mar. 29, 2017 /PRNewswire/ — CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced the completion of a $20 million round in equity financing.